ESMO Symposium on Immuno-Oncology 2016

Oncology Meeting Resources

04 Nov - 06 Nov 2016, Lausanne, Switzerland

ESMO Immuno Oncology 2016 Square

ESMO Symposium on Immuno-Oncology 2016 underlined ESMO’s commitment to educate cancer physicians and researchers in a rapidly evolving area of treating cancer through immunotherapy and offered an update on the latest developments in immuno-oncology in an effort to bring innovative approaches directly to patients.

Abstracts, presentations and webcasts from the ESMO Symposium on Immuno-Oncology 2016 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...Oncology-2016/Impact-of-tumour-heterogeneity

Date: 04 Nov 2016
Presenter: Marco Gerlinger
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...gether-Combinations-of-checkpoint-inhibitors

Date: 04 Nov 2016
Presenter: Omid Hamid
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ination-of-checkpoints-and-immunostimulation

Date: 04 Nov 2016
Presenter: Ignacio Melero
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ic-malignancies-NCT02572687-Phase-1a-results

Aim/BackgroundSimultaneously targeting angiogenesis and immunosuppression demonstrates a synergistic antitumor effect in preclinical models. Preliminary safety results from the phase 1a portion of this...

Date: 04 Nov 2016
Presenter: Chia-Chi Lin
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-2016/Invited-discussant-abstracts-1O-and-2O

Date: 04 Nov 2016
Presenter: John Haanen
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...via-CRISPR-Cas9-mediated-genetic-engineering

Aim/BackgroundIn response to the constant antigen stimulation given by tumours or chronic viral infections, T cells usually malfunction. It is now clear that tumours co-opt certain immune checkpoint...

Date: 04 Nov 2016
Presenter: Chi Zhang
Resources: Abstract, Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ccines-with-a-new-epitope-improvement-system

Aim/BackgroundCancer vaccines induce an immune response against specific tumor antigens, which might also be self-antigens. Hence T-cells are either not trained to recognize them (i.e.

Date: 04 Nov 2016
Presenter: Cristian Capasso
Resources: Abstract, Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ential-than-current-HER2-targeting-therapies

Aim/BackgroundCurrent HER2-targeting therapies (such as Herceptin or TDM-1) have demonstrated efficacy only in cancers significantly overexpressing HER2 (cancers characterized as HER2 3+ according to...

Date: 04 Nov 2016
Presenter: Jonathan Back
Resources: Abstract, Presentation

http://oncologypro.esmo.org/Meeting-Resourc...-effects-in-nivolumab-treated-NSCLC-patients

Aim/BackgroundTreatment with PD-1 inhibitors is sometimes hampered by severe auto-immune related adverse events (AEs) compromising treatment outcomes. The objective of the current analysis was to...

Date: 04 Nov 2016
Presenter: Sander Bins
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ns-Attacking-tumour-immune-escape-mechanisms

Date: 05 Nov 2016
Presenter: William Grossman
Resources: Presentation, Webcast